TABLE 4.

The effect of AP-32, RM, and A-RM on fecal SCFAs profiles after 8 weeks of treatments.

SCFAs (mM)	NC	PD	L	AP-32	RM	A-RM
Total acid	6.43 ± 0.64	4.48 ± 1.37#	5.38 ± 1.28	6.39 ± 0.42*	6.42 ± 0.87*	6.50 ± 1.73*
Acetic acid	4.33 ± 0.61	3.63 ± 1.36	3.99 ± 0.92	4.49 ± 0.53	4.96 ± 0.79	4.92 ± 0.90
Propionic acid	1.06 ± 0.06	0.58 ± 0.16#	0.95 ± 0.12*	0.93 ± 0.10*	1.00 ± 0.07*	1.16 ± 0.37*
Isobutyric acid	0.03 ± 0.01	0.03 ± 0.00	0.03 ± 0.01	0.05 ± 0.01*	0.04 ± 0.02	0.04 ± 0.01
Butyric acid	1.80 ± 0.13	0.54 ± 0.11#	0.90 ± 0.38	1.57 ± 0.38*	1.23 ± 0.21*	1.21 ± 0.61*
Isovaleric acid	0.02 ± 0.00	0.01 ± 0.00	0.01 ± 0.01	0.03 ± 0.01*	0.03 ± 0.01*	0.02 ± 0.00
Valeric acid	0.08 ± 0.01	0.06 ± 0.01	0.05 ± 0.01	0.07 ± 0.02	0.05 ± 0.03	0.05 ± 0.02

Data are expressed as mean ± SEM (n = 5 rats/group). ^#p < 0.05 PD group compared to NC group. *p < 0.05 L, AP-32, RM, and A-RM groups compared to PD group. There is no significant difference between AP-32, RM, and A-RM. One-way ANOVA with Tukey’s post hoc test. SCFAs, short-chain fatty acids.